• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌组织的表达谱分析确定了与前列腺切除术后复发相关的基因。

Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.

作者信息

Mortensen Martin Mørck, Høyer Søren, Lynnerup Anne-Sophie, Ørntoft Torben Falck, Sørensen Karina Dalsgaard, Borre Michael, Dyrskjøt Lars

机构信息

Department of Molecular Medicine, Aarhus University Hospital, Brendstrupgårdsvej 100, DK-8200 Aarhus N, Denmark.

Department of Urology, Aarhus University Hospital, Brendstrupgårdsvej 100, DK-8200 Aarhus N, Denmark.

出版信息

Sci Rep. 2015 Nov 2;5:16018. doi: 10.1038/srep16018.

DOI:10.1038/srep16018
PMID:26522007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4629186/
Abstract

Prostate cancer is a leading cause of cancer death amongst males. The main clinical dilemma in treating prostate cancer is the high number of indolent cases that confer a significant risk of overtreatment. In this study, we have performed gene expression profiling of tumor tissue specimens from 36 patients with prostate cancer to identify transcripts that delineate aggressive and indolent cancer. Key genes were validated using previously published data and by tissue microarray analysis. Two molecular subgroups were identified with a significant overrepresentation of tumors from patients with biochemical recurrence in one of the groups. We successfully validated key transcripts association with recurrence using two publically available datasets totaling 669 patients. Twelve genes were found to be independent predictors of recurrence in multivariate logistical regression analysis. SFRP4 gene expression was consistently up regulated in patients with recurrence in all three datasets. Using an independent cohort of 536 prostate cancer patients we showed SFRP4 expression to be an independent predictor of recurrence after prostatectomy (HR = 1.35; p = 0.009). We identified SFRP4 to be associated with disease recurrence. Prospective studies are needed in order to assess the clinical usefulness of the identified key markers in this study.

摘要

前列腺癌是男性癌症死亡的主要原因之一。治疗前列腺癌的主要临床困境在于大量惰性病例存在过度治疗的重大风险。在本研究中,我们对36例前列腺癌患者的肿瘤组织标本进行了基因表达谱分析,以鉴定区分侵袭性和惰性癌症的转录本。关键基因通过先前发表的数据和组织微阵列分析进行了验证。我们鉴定出两个分子亚组,其中一组中生化复发患者的肿瘤明显过多。我们使用两个总计669例患者的公开可用数据集成功验证了关键转录本与复发的关联。在多变量逻辑回归分析中,发现12个基因是复发的独立预测因子。在所有三个数据集中,复发患者的分泌型卷曲相关蛋白4(SFRP4)基因表达均持续上调。我们使用536例前列腺癌患者的独立队列显示,SFRP4表达是前列腺切除术后复发的独立预测因子(风险比=1.35;p=0.009)。我们确定SFRP4与疾病复发相关。需要进行前瞻性研究,以评估本研究中鉴定出的关键标志物的临床实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/748b3b060b76/srep16018-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/cefb03053772/srep16018-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/cf1e6a342308/srep16018-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/748b3b060b76/srep16018-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/cefb03053772/srep16018-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/cf1e6a342308/srep16018-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a802/4629186/748b3b060b76/srep16018-f3.jpg

相似文献

1
Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.前列腺癌组织的表达谱分析确定了与前列腺切除术后复发相关的基因。
Sci Rep. 2015 Nov 2;5:16018. doi: 10.1038/srep16018.
2
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.用于预测局限性前列腺癌根治术后生化复发的 DNA 甲基化特征。
J Clin Oncol. 2013 Sep 10;31(26):3250-8. doi: 10.1200/JCO.2012.47.1847. Epub 2013 Aug 5.
3
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.前列腺癌中SLC18A2基因和表观遗传沉默是根治性前列腺切除术后生化复发的独立不良预测因素。
Clin Cancer Res. 2009 Feb 15;15(4):1400-10. doi: 10.1158/1078-0432.CCR-08-2268.
4
High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.前列腺癌中高表达的miR-449b与前列腺癌根治术后的生化复发相关。
BMC Cancer. 2014 Nov 21;14:859. doi: 10.1186/1471-2407-14-859.
5
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.多中心临床验证 PITX2 甲基化作为前列腺癌根治术后前列腺癌患者前列腺特异性抗原复发预测因子。
J Urol. 2010 Jul;184(1):149-56. doi: 10.1016/j.juro.2010.03.012. Epub 2010 May 15.
6
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.启动子高甲基化作为前列腺癌根治术后患者复发的独立预后因素。
Clin Cancer Res. 2005 Dec 1;11(23):8321-5. doi: 10.1158/1078-0432.CCR-05-1183.
7
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.前列腺癌中 GABRE~miR-452~miR-224 启动子的高甲基化预测根治性前列腺切除术后的生化复发。
Clin Cancer Res. 2014 Apr 15;20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642.
8
Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.循环肿瘤细胞簇中抗氧化基因表达水平对 PSA 水平在 4-10ng/ml 的前列腺癌患者和根治性前列腺切除术后疾病预后检测的临床应用价值。
BJU Int. 2010 Apr;105(7):1000-10. doi: 10.1111/j.1464-410X.2009.08920.x. Epub 2009 Oct 10.
9
8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.8q24 扩增与 Myc 表达和前列腺癌进展相关,是前列腺癌根治术后复发的独立预测因子。
Hum Pathol. 2013 Aug;44(8):1617-23. doi: 10.1016/j.humpath.2013.01.012. Epub 2013 Apr 8.
10
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.前列腺癌中候选易感基因HNF1β和CtBP2的表达模式:与肿瘤进展的关联
Urol Oncol. 2014 May;32(4):426-32. doi: 10.1016/j.urolonc.2013.09.006. Epub 2013 Dec 12.

引用本文的文献

1
Single-Cell and Bulk RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Malignant Progression Mechanisms in Prostate Cancer.单细胞和批量RNA测序揭示前列腺癌的肿瘤内异质性和恶性进展机制
J Cell Mol Med. 2025 Aug;29(16):e70806. doi: 10.1111/jcmm.70806.
2
Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancer.用于前列腺癌精准预后的免疫微环境和耐药特征的综合多组学分析
Cancer Drug Resist. 2025 Jun 25;8:31. doi: 10.20517/cdr.2025.47. eCollection 2025.
3
Using machine learning to discover DNA metabolism biomarkers that direct prostate cancer treatment.

本文引用的文献

1
A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.一种 17 基因检测方法,可在格里森分级异质性、肿瘤多灶性和活检取样不足的情况下预测前列腺癌的侵袭性。
Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.
2
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.发现并验证一种前列腺癌基因组分类器,可预测根治性前列腺切除术后的早期转移。
PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.
3
Activin receptor antagonists for cancer-related anemia and bone disease.
利用机器学习发现指导前列腺癌治疗的DNA代谢生物标志物。
Sci Rep. 2025 Jul 18;15(1):26117. doi: 10.1038/s41598-025-11457-1.
4
Knowledge-guided multi-level network modeling with experimental characterization identifies PRKCA as a novel biomarker and tumor suppressor triggering ferroptosis in prostate cancer.通过实验表征进行知识引导的多层次网络建模确定PRKCA为一种新型生物标志物和触发前列腺癌铁死亡的肿瘤抑制因子。
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf220.
5
Exploring the impact of cuproptosis on prostate cancer prognosis RNA methylation regulation based on single cell and bulk RNA sequencing data.基于单细胞和批量RNA测序数据探索铜死亡对前列腺癌预后的影响及RNA甲基化调控
Front Pharmacol. 2025 Apr 1;16:1573611. doi: 10.3389/fphar.2025.1573611. eCollection 2025.
6
CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancer.CTHRC1在癌症相关成纤维细胞中表达,并与前列腺癌抗雄激素治疗耐药相关。
Genes Genomics. 2025 May;47(5):541-557. doi: 10.1007/s13258-025-01624-z. Epub 2025 Feb 26.
7
Analysis of microarray and single-cell RNA-seq identifies gene co-expression, cell-cell communication, and tumor environment associated with metabolite interconversion enzyme in prostate cancer.微阵列和单细胞RNA测序分析确定了与前列腺癌中代谢物相互转化酶相关的基因共表达、细胞间通讯和肿瘤环境。
Discov Oncol. 2025 Feb 13;16(1):177. doi: 10.1007/s12672-025-01926-4.
8
DPH2 is a biomarker associated with cell death, immunity and prognosis based on pan-cancer analysis.基于泛癌分析,DPH2是一种与细胞死亡、免疫和预后相关的生物标志物。
Discov Oncol. 2025 Feb 10;16(1):149. doi: 10.1007/s12672-025-01924-6.
9
Exploring the causal role of plasma metabolites and metabolite ratios in prostate cancer: a two-sample Mendelian randomization study.探索血浆代谢物及代谢物比率在前列腺癌中的因果作用:一项两样本孟德尔随机化研究
Front Mol Biosci. 2025 Jan 6;11:1406055. doi: 10.3389/fmolb.2024.1406055. eCollection 2024.
10
Elevated miR-221-3p inhibits epithelial-mesenchymal transition and biochemical recurrence of prostate cancer via targeting KPNA2: an evidence-based and knowledge-guided strategy.升高的miR-221-3p通过靶向核转运蛋白α2抑制前列腺癌的上皮-间质转化和生化复发:一种基于证据和知识引导的策略
BMC Cancer. 2025 Jan 8;25(1):34. doi: 10.1186/s12885-025-13444-1.
激活素受体拮抗剂在癌症相关贫血和骨疾病中的应用。
Expert Opin Investig Drugs. 2013 Jan;22(1):87-101. doi: 10.1517/13543784.2013.738666. Epub 2012 Nov 6.
4
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.破骨细胞 Wnt/β-连环蛋白信号通路的抑制是肾性骨营养不良进展过程中的早期事件。
J Bone Miner Res. 2012 Aug;27(8):1757-72. doi: 10.1002/jbmr.1630.
5
Wnt signaling in cancer.Wnt 信号通路与癌症。
Cold Spring Harb Perspect Biol. 2012 May 1;4(5):a008052. doi: 10.1101/cshperspect.a008052.
6
Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.分泌型卷曲相关蛋白 4 的缺失与卵巢癌患者侵袭性表型相关,并预示不良预后。
PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.
7
Molecular classification of prostate cancer using curated expression signatures.基于经整理的表达特征对前列腺癌进行分子分类。
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21276-81. doi: 10.1073/pnas.1117029108. Epub 2011 Nov 28.
8
Activins and activin antagonists in the prostate and prostate cancer.激活素和激活素拮抗剂在前列腺和前列腺癌中的作用。
Mol Cell Endocrinol. 2012 Aug 15;359(1-2):107-12. doi: 10.1016/j.mce.2011.07.005. Epub 2011 Jul 20.
9
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
10
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.基于细胞周期增殖基因的 RNA 表达特征对前列腺癌患者预后价值的回顾性研究。
Lancet Oncol. 2011 Mar;12(3):245-55. doi: 10.1016/S1470-2045(10)70295-3.